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Autoantibodies to type VII collagen are characteristic of the 
blistering diseases epidermolysis bullosa acquisita and bullous 
systemic lupus erythematosus (SLE). Blisters in those diseases 
are due to defective adhesion of the lamina densa subregion of 
the epithelial basement membrane to the underlying dermis. 
Previous studies indicating that type VII collagen contributes 
to lamina densa-dermal adhesion by cross-linking lamina 
densa and dermal matrix proteins suggests that autoanti-
bodies may contribute to blisters by interfering with type VII 
collagen function. That hypothesis is supported by previous 
studies showing autoantibodies from a small number of epi-
dermolysis bullosa acquisita patients recognize proteolytic 
E
pidermolysis bullosa acquisita (EBA) and bullous sys-
temic lupus erythematosus (SLE) are relatively rare au-
toimmune blistering diseases of stratified squamous 
epithelia (reviewed in [1,2)). Both diseases are character-
ized by circulating and tissue-bound IgG autoantibodies 
to the epithelial basement membrane. Previous studies have shown 
that basement membrane antibodies in EBA react with type VII 
collagen (C7), and indicate that basement membrane antibodies in 
bullous SLE have the same specificity [3,4]. Histologic studies have 
shown that blisters in these diseases result from separation of the 
epidermis from the dermis at the level of the epithelial basement 
membrane [1,2]. Electron microscopic studies of the epithelial base-
ment membrane region show that epidermal-dermal separation is 
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Abbreviations: 
BSA: bovine serum albumin 
C7: type vn collagen 
EBA: epidermolysis bullosa acquisita 
ELISA: enzyme-linked immunosorbent assay 
Fn III: type III fibronectin repeats 
lPTG: isopropyl-beta-D-thiogalactopyranoside 
NC1: 145-kD non collagenous domain/type VII coHagen 
PBS: phosphate-buffered saline 
PCR: polymerase chain reaction 
50S-PAGE: sodium dodecylsuifate- polyacrylamide gel electro-
phoresis 
SLE: systemic lupus erythematosus 
vWf: von Willebrand factor 
fragments containing the 145-kD noncollagenous domain of 
type VII collagen. In this study, we examined reactivity of 
autoantibodies from a large number of epidermolysis bullosa 
acquisita and bullous SLE patients with fusion proteins repre-
senting most of the noncollagenous domain of type VII col-
lagen and that those regions are homologous to type III re-
peats of fibronectin. These results suggest autoantibodies 
binding to fibronectin homology regions within the 145-kD 
noncollagenous domain may interfere with the adhesion 
function of type VII collagen and contribute to lamina 
densa - dermal dysadhesion in epidermolysis bullous acquis-
ita and bullous SLE.] Invest DermatoI100:6 18-622, 1993 
due to dysadhesion of the lamina densa subregion of the basement 
membrane from the upper dermis [1,2]. The increasing evidence 
that C7 contributes to normal lamina densa-dermal adhesion sug-
gests C7 autoantibodies may contribute to blisters in EBA and bul-
lous SLE by interfering with C7 function. 
Collagen VII is an epithelial basement membrane-restricted pro-
tein composed of three identical alpha chains, each consisting of an 
amino-terminal 145-kDa noncollagenous (NC1) domain and a 
145-kDa carboxyl-terminal collagenous domain [5,6]. Molecules of 
C7 aggregate ill vivo to form morphologically distinctive fibrillar 
structures called anchoring fibrils [5 ,7,8]. The ends of anchoring 
fibrils associate with the lamina densa and with dermal structures 
called anchoring plaques, resulting in the formation of a sub-lamina 
densa fibrillar network that appears to "anchor" the lamina densa to 
the dermis [9] . A role for C7 in lamina densa - dermal adherence is 
supported by an association between defective lamina densa-
dermal adhesion and abnormal expression of anchoring fibrils and 
immunoreactive C7 in patients with inherited forms of dystrophic 
epidermolysis bullosa [10]. Recent gene mapping studies indicate 
that these diseases are due to a defect in the C7 gene [11] . Interest-
ingly, the clinical, pathologic, and ultrastructural features of skin 
lesions in patients with dominantly inherited dystrophic epidermo-
lysis bullosa closely resemble those features in some EBA patients 
[1,10]. 
The adherence role for C7, evidence that a genetic defect in C7 
contributes to lamina densa - dermal dysadhesion in dystrophic 
forms of EB, and similarities between patients with dystrophic epi-
dermolysis bullosa and patients with autoantibodies to C7 suggests 
the autoantibodies may contribute to lamina densa -dermal dysad-
hesion by interfering with the adherence function of C7. Thaf 
hypothesis is supported by a recent study showing that C7 antibod-
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figure 1. Schemati~ of the CVII-~ eDNA showing 7t Fn repeats (_) 
consisting of approXImately 90 ammo aClds per repeat at the 5' end, and a 
single A domain homology region (_) consisting of approximately 
190 amino acids at the 3' end. The location of gene 10 (pGm) and glutathi-
one transferase (pGx) fusion proteins relative to CVII-1 homology regions 
is shown (c==J) above and below the CVIl-1 homology regions. ::':':"':" 
at the bottom of the figure indicates regions recognized by most autoim-
mune sera . The corresponding beginning (5') and ending (3 ') nucleotides 
for each of the fusion proteins are as follows: pGm2.4 and pGx2.4 (nts 
1-2255); pGm1.4 (nts 1-1250); pGml.l (nts 1644-2661); pGmO.7 (nts 
1644- 2255); pGx327 (nts 1-327); pGx673 (nts 1-673); pGx884 (nts 
1-884); pGx773 (nts 868 - 1641); pGx298 (nts 1372-1665); pGx620 (nts 
1372-1987); pGx1253 (nts 1372 -2273), and pGx708 (nts 1901-2661). 
'es from several patients with EBA react with proteolytic fragments 
:hat contain the NC1 but not the collagenous domain of C7 [3] . 
The NC1 domain is the region of C7 that appears to link anchoring 
fibrils to the lamina densa and the dermis by interacting with lamina 
densa and dermal matrix proteins such as type IV collagen [9,12,13]. 
A role for the NC1 domain in mediating interactions between C7 
and other matrix proteins suggests C7 autoantibodies might contrib-
ute to lamina densa - dermal dysadhesion by targeting functional 
regions of the NC1 domain. In this study, epitope regions recog-
nized by antibodies from 12 EBA and bullous SLE patients were 
mapped using fusioll proteins corresponding to most of the NC1 
domain of C7. 
MATERIALS AND METHODS 
Antibodies Sera containing autoantibodies to the epithelial base-
ment membrane of stratified squamous epithelia were obtained 
from seven EBA and five bullous SLE patients. Titers of the antibod-
ies were determined by indirect immunofluorescence on 1.0 M 
NaCI-split normal human skin as previously described and ranged 
becween 1 : 80 and 1 : 1280 [14]. All of the sera contained antibodies 
w the dermal side of split skin by indirect immunofluorescence and 
reacted with tissue C7 or proC7 by Western immunoblotting or 
immunoprecipitation as previously described [13,15J. Control sera 
were obtained from three EBA patients without detectable circulat-
ing anti-b~sement membran~ antibodies, three patients ,:"ith .bullous 
pemphigoid who have anti-basement membrane antibodIes that 
larget hemidesmosome-associated antigens, three patients with ac-
live SLE, and three normal humans. A previously characterized 
murine monoclonal antibody, L3d, that reacts with the NC1 do-
main of C7 was used as an additional control [16] . 
eDNA and DNA Fragments A previously described partial C7 
eDNA (CVIl-l) was used as a source of DNA fragments [13] . CVII-
1(2661 nts) encodes an estimated 75% of NC1 beginning down-
Ilream of the 5' start site and ending at the beginning of the collage-
noUS domain. It encodes (5' > 3') 7! sequential fibronectin 1II (FN 
110 repeats of 90 amino acids each fo llowed by a von Willebrand 
&etor (vWf) A- like domain homology region of 190 amino acids 
(Fig 1) [13]. DNA corresponding to different regions of CVIl-1 was 
prepared for cloning by restriction endonuclease digestion, exonu-
clease III digestion using the Erase-a-Base System (Promega Corp), 
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and DNA amplification by the polymerase chain reaction (PCR) 
[17 - 19J. 
F~sion Proteins DNA fragments corresponding to indicated re-
gIOns of the CVII-1 cDNA (Fig 1) were cloned into pGEMEX1 
(Promega Corp) and pGEX-2T (Pharmacia) respectively using in-
structions provided by the suppliers . pGEMEXl gene 10 (pGm) and 
PGEX-~T glutatluone S-transferase (pGx) fusion proteins were ex-
pressed mJM109(DE3) Escherichia coli cells following addition of 
Isopropyl-beta~D-thlOga lactopyranoside (IPTG) to log-phase cul-
tures. RecombInant clones were screened by SDS-PAGE of bacterial 
lysates and by immunoblotting with a rabbit antibody to the pGE-
MEXl gene 10 proteIn (Novagen) ; a monoclonal antibody (L3d) to 
the NC1 domaIn of C7; and a reference EBA serum E007 con-
taining high-titer antibodies to C7 and CVII-l fusio~ protei~ [13]. 
Gene .1 0 proteIns were screened for expression of C7 and/or gene 
10 epltopes at or near the predicted mass. Glutathione transferase 
proteins were ~f!i.nity purified by absorption on glutathione Sepha-
rose (Pharmacla) and assayed by SDS-PAGE and immunoblotting 
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Figure 2. A: Western blots of sera (a -I) containing C7 antibodies against 
pGm2.4 (all lanes labeled " 1") and pGml.4 (all lanes labeled " 2" ). Top 
row: a -f correspond to sera E-IG, E-He, S-Jo, E-Te, E-Br, and S-Ra, respec-
tlVely. Bortom row: g-l correspond to sera S-Ca E-Si S-Re E-Su E-Sh and 
S-De, respecti:ely. Sera ~th a basement ~emb~ane ~ntibody tit~r of 
greater than 1.100 by mdirect Immunofluorescence were used at a dilu-
tion of 1 : 100 and Sera with a titer of less than 1: 100 were used at a 
dilution of 1 : 20 . Control sera (not shown) did not label either the 125 or 
97 kD bands. B: Western blots against fusion protein pGml.l (66 kO). 
EB~ and bullous SLE sera containing basement membrane antibodies are 
des.lgna~ed by E and S respectively. Control (C) sera were negative for C7 
antibodies. C-Ma and C-Yo are two EBA sera without basement mem-
brane antibodies by indirect immunofluorescence. C-BP-St is a bullous 
pemphigoid serum with basement membrane antibodies against the bul-
lous pemphigoid antigen (titer > 1 : 640). C-L3d is a monoclonal antibody 
reactive with the NCI domain of C7. Control sera were used at a dilution 
of 1 : 20. Othersera were used at dilutions of 1 : 20 or 1 : 100. Faint staining 
of pGml.l could occasionally be observed with 1: 20 dilutions of normal 
human sera, e .g. , C-NHS; therefore, reactions were interpreted as positive 
only if staining was stronger than C-NHS. 
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Table I. EBA (E) and Bullous SLE (S) Serum Reactivity with 
eVIl-l Fusion Proteins' 
Serum pGm2.4 pGm1.4' pGm1.l ' 
E-Ki +/+b + + 
E-He +/+ + + 
E-Br +/+ + + 
E-Su +/+ + + 
E-Si +/+ + 
E-Sh +/+ + 
E-Te -/-
S-De +/+ + 
S-Ca +/+ + + 
S-Ra +/+ + + 
S-}o +/+ + + 
5-Re +/+ + + 
. +, positive; -, negative. 
• Blotting results/ELISA results. 
, Blotting results only. 
with C7 antibodies. The structure of fusion proteins containing 
PCR-amplified DNA were confirmed by DNA sequencing [19]. 
Western Immunoblotting Serum and monoclonal antibodies 
were assayed against gene 10 and glutathione transferase CVII-1 
fusion proteins by immunoblotting as previously described [13]. 
Enzyme-Linked Immunosorbant Assay (ELISA) Affinity-
purified glutathione transferase fusion proteins in 0.1 M carbonate 
buffer, pH 9.6 (coating buffer), were incubated at 4 °C overnight in 
96-well polystyrene ELISA plates (Costar) . The wells were exhaus-
tively washed with phosphate-buffered saline, pH 7.4, containing 
0.05% tween 20 and 0.25% bovine serum albumin (PBS-tween-
BSA), and blocked with PBS-tween-BSA. Blocked wells were incu-
bated with sera or monoclonal antibodies diluted in PBS-tween-
BSA, and washed with PBS-tween-BSA. After washing, antibody 
binding was detected using an appropriate species-specific alkaline 
phosphatase - conjugated anti-IgG secondary antibody and devel-
oped with p-nitrophenyl phosphate [20] . 
RESULTS AND DISCUSSION 
Characterization of CVII-1 Fusion Proteins Four gene 10 
(pGm) and 9 glutathione S-transferase (pGx) fusion proteins were 
prepared from CVII-l DNA. The designations, relationships to 
N C 1 homology regions, and beginning and ending nts are shown in 
Fig 1. Gene 10 fusion proteins pGm2.4, pGm1.4, and pGm1.1 
collectively represented all of the NCl domain of C7 encoded by 
the CVII- l eDNA. pGm2.4 encoded the entire Fn III homology 
region and a portion of the vwf A-like domain. pGm1.4 encoded 
the first 41' Fn III repeats. pGm 1.1 encoded the last 1 l' Fn III repeats 
and all of the A domain. pGmO.7 encoded the first half of the region 
encoded by pGm 1.1. The glutathione transferase fusion proteins 
included 1) two sets (set I, pGx327, pGx673, pGx884; and set II, 
pGx298, pGx620, pGx1253) of three partially overlapping fusion 
proteins representing most of the N- and C-termini, respectively, of 
the Fn III homology region; 2) pGx708 corresponding to the A 
domain; 3) pGx773 corresponding to the Fn III homology region 
between set I and set II fusion proteins; and 4) pGx2.4 identical to 
pGm2.4. 
EBA and Bullous SLE IgG Antibodies, Recognize Fusion 
Proteins Encoded by Non-Overlapping Regions of the CVII-
1 eDNA Seven EBA and five bullous SLE sera containing IgG 
basement membrane antibodies were immunoblotted against 
pGm2.4, pGm1.4, and pGm1.1 fusion proteins. The results (Fig 2 
and Table I) showed that 11 sera (six EBA and five bullous SLE) 
recognized pGm2.4 and pGm 1.1. Sera that recognized pGm2.4 
were also found to react by ELISA with pGx2.4 (Table I). Eight of 
the 11 sera (four EBA and four bullous SLE) also recognized 
pGm 1.4 by blotting. The three sera that blotted pGm 1.1 but not 
pGm1.4 were subsequently found to react by ELISA with set I pGx 
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Table II. EBA (E) and Bullous SLE (S) Serum Reactivity with 
eVIl -1 Fusion Proteins' 
Set I Set II 
Sera pGx327 pGx673 pGx884 pGx298 pGx620 pGx1253 
E-Ki -/- +/+ +/+ +/+ +/+ +/+ 
E-He -/- +/+ +/+ -/- +/+ +/+ 
E-Br -/- +/+ +/+ -/- +/+ +/+ 
E-Su -/- -/+ +/+ -/- -/+ -/+ 
E-Si -/- -/NDb -/+ -/- +/+ +/+ 
E-Sh -/- -/ND -/ND -/- +/+ +/+ 
E-Te -/- -/- -/- -/- -/- -/-
5-De -/- -/- -/+ -/+ +/+ +/+ 
S-Ca -/- -/- +/+ -/- +/+ +/+ 
S-Ra -/- -/- -/+ -/- +/+ +/+ 
5-}0 -/- -/+ +/+ -/- +/+ +/+ 
S-Re -/- -/+ +/+ -/- -/- +/+ 
• Blotting results/ELISA results. +, positive; -, negative. 
• ND, not done. 
fusion proteins (Figs 1 and 4 and Table II) . indicating that those sera 
recognized epitopes in pGm1.4. Serum E-Te (anti-basement mem-
brane antibody titer, 1: 80) and negative control sera did not recog-
nize any of the proteins. Affinity absorption of serum E-K.i on nitro-
cellulose coated with purified pGx2.4 removed all anti-basement 
membrane antibody and anti-pGx2.4 activity as assessed by indirect 
immunofluorescence and ELISA, respectively, and the eluted IgG 
showed strong anti-basement membrane and anti-pGx2.4 activity 
(results not shown). 
These results show that more than 90% of EBA and bullous SLE 
sera containing C7 antibodies react with fusion particles corre-
sponding to the CVII-1 cDNA. The finding that eight of the sera 
(> 70% of reactive sera) recognized fusion proteins (pGm 1.4 and 
pGm1.1) containing non-overlapping sequences indicates that at 
least two regions within NC1 are recognized by most EBA and 
bullous SLE sera. The absence of reactivity by serum E-Te indicates 
there may be additional epitopes outside the region encoded by 
CVII-l or that other epitopes may be dependent on confirmational 
or post-translational modifications not present in these fusion pro-
teins. The finding that anti-basement membrane antibodies could 
be completely absorbed from the high-titer (1: 640) serum E-Ki 
with pGx2.4 indicates that pGx2.4 contains all the major epitopes 
recognized by circulating C7 antibodies from that patient and that 
post-translational changes are not necessary for the formation of 
those epitopes. 
Epitopes Recognized by EBA and Bullous SLE Antibodies 
Consist ofFn III Sequences To further characterize regions of 
NC1 recognized by C7 antibodies, we tested EBA and bullous SLE 
sera for reactivity against fusion proteins from sets I (nts 1-884) and 
II (nts 1372-2273), pGx 773 (nts 868-1641) and pGx708 (nts 
Table III. EBA (E) and Bullous SLE (S) Serum Reactivity with 
eVIl-l Fusion Proteins' 















• Blotting results/ELISA results. +, positive; -, negative. 
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. 3 Representative examples of western blots of EBA and bullous Flgure . . . Th 
LE sera (A-C), and L3d (D) against pGm ~nd pGx fUSIOn protems. e 
5 5 are labeled (left > right) with the fUSIOn protem fragments as fol· 
:~:,es : lane 1, 2400 (pGm2400); lalle 2, 884 (pGx884); lalle 3, 673 (pGx673); 
I 4 1100 (pGm 1.1); lalle 5, 700 (pGmO.7); lalle 6, 620 (pGx620); lallc 7, 
;;~ (pHx298); lalle 8, 708 (pGx708). Refer to Fig 1 for location of frag· 
ts The molecular weights of corresponding fragments are labeled at 
~:~ef't of each set of lanes A-D. Interpretation of reactivity (+) or lack of 
ctivity (-) is listed at the bottom of each lane. A shows bl~ts performed 
re;h serum from EBA patient E·Si. This serum only reacts with fragments 
Wl taining the sequence found within the set II fusion protem, pGx620. B 
con . f . ESThi shoWS blots performed with serum rom EBA patient -. u. s serum 
ts with fragments containing the sequences found m set I fUSIOn 
rea~ein pGx884 and the set II fusion protein pGx620. C shows blots 
proformed with serum from bullous SLE patient, S-Re. This serum only 
per ts with fragments containing the set I fusion protein pGx884. Dshows 
reaC . . I ' h h monoclonal antibody to the NCI domam of C7, L3d, on y reacts Wit 
}U:ion proteins containing the sequences present in the set II fusion pro-
tein pGx620. 
1901- 2661), by both immunoblotting and ELISA. Comparison of 
the immunoblotting and ELISA results (Tables II and Ill) showed 
the methods were IJ1 general agreement .but the E~ISA appeared to 
be more sensitive. Of the 79 assays IJ1 which reactiVity was measured 
b both methods, the results agreed in 68 cases (84%). In the re-
rJaining 11 cases, the ELISA was positive and the immunoblot was 
negative. 
Immunoblot analysis of set I fusion proteins showed seven sera 
(E-Ki, E-He, E-Br, E-Su, S-Ca, S-Jo, and S-Re) recognized pGx884, 
three of those sera (E-Ki, E-He, and E-Br) recogI1lzed pGx673, but 
none recognized pGx327 (Fig 3 and Table II). By ELISA, three 
additional sera (E-Si, S-De, and S-Ra) reacted with pGx884 and 
three others (E-Su , S-Jo, and S-Re) reacted with pGx 673 (Fig 4 and 
Table II). Immunoblot analysis of set II fusion proteins showed 10 
sera (E-Ki, E-He, E-Br, E-Si, E-Sh, S-De, S-Ca, S-Ra, S-Jo, and 
S-Re) recognized pGx1253 (Table II). N111e of those sera (all but 
S-Re) also recognized pGx620, whereas only one serum ~E-KI) 
recognized pGx298 (Fig 3 and Ta?le II). By ELISA, one additIOnal 
serum reacted with each of the fUSIOn prote111s (S-De With pGx298, 
E-Su with pGx620 and pGx12S3) (Fig 4 and Table II) . None of 
these se ra reacted with pGx708 and on ly three sera (S-De, S-Jo, and 
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S-Re) reacted with pGx773 (Fig 3 and Table IV). Neither serum 
E-Te nor negative control sera reacted with any of these proteins by 
immunoblotting or ELISA. 
The reactivity of EBA and bullous SLE sera with pGx fusion 
proteins confirmed the results with pGm 1.4 and pGm 1.1 fusion 
proteins by showing that at least two non-overlapping regions in 
the NC1 domain of C7 are recognized by C7 antibodies. These 
results also showed th at the two major epitope regions are located 
between the amino acids encoded by nts 327 - 884 and nts 1665-
1987. The region between nts 327 and 884 consists of 186 amino 
acids and appears to contain more than one epitope since four sera 
reacted with pGx884 but did not react with pGx673. This differen-
tial reactivity indicates that non-repetitive epitopes may reside in 
pGx673 and pGx884 and suggests that the autoantibody response to 
C7 may be antigen driven. The 3' end of the second major epitope 
region probably lies upstream of nt 1901 rather than nt 1986 be-
cause none of the sera that reacted with this region recognized 
pGx708, which begins at nt 1901. Consequently, the region may 
consist of 79 amino acids. Interestingly, this region was also recog-
nized by the L3d monoclonal antibody [16]. 
The findings that pGx884 and pGx620 were recognized by most 
EBA and bullous SLE sera and that both fragments contained Fn III 
repeats suggested epitopes in these fragments were cross-reative. 
However, a comparison of amino acid sequences between those two 
fragments showed no regions with more than three sequential iden-
tical amino acids. Furthermore, in preliminary studies (results 
not shown) in which serum E-Ki was selectively absorbed on and 
eluted from nitrocellulose-bound purified pGx884 and pGx620, 
ELISA assay of the absorbed and eluted fractions showed no evi-
dence of cross-reactivity against pGx884 and pGx620. These find-
ings indicate that the epitopes within these fragments are dis-
tinct. 
These results conclusively demonstrate that bullous SLE as well as 
EBA basement membrane antibodies recognize C7 and show both 
types of antibodies recognize epitopes in the region of the NC1 
domain of C7 containing a series of sequential Fn III repeats. Prelim-
inary evidence indicates multiple, distinct epitopes are recognized. 
None of the sera unambiguously reacted with pGx708, which 
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Figure 4. Results of ELISA assay of five EBA (Ki, He, Su, Br, Te) and five 
bullous SLE (Re, Ca, Jo, De, Ra) sera containing basement membrane 
antibodies against C7, and five control sera including two EBA sera with-
out circulating basement membrane antibodies (Yo and Va), two bullous 
pemphigoid sera with antibodies to the bullous pemphigoid antigen (MI 
and eh), and one normal human serum (NHS). The sera were tested 
against purified glutathione transferase fusion protein pGx673, which is a 
set I fusion protein containing CVII-1 nts 1- 673. EBA and bullous SLE 
sera were diluted 1 : 20 if the basement membrane antibody titer was less 
than 1 : 100. If the titer was greater than 1 : 100, they were diluted 1 : 100. 
All control sera were diluted 1 : 20. Closed bars, reactivity of sera With 
purified fusion proteins; opell bars, reactivity with purified glutathione 
transferase. 
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several sera reacted with pGx1253, which contains the pGx708 
region. All but one, S-Re, of those sera reacted with the pGx620 
fragment which contains sequences that are mainly 5' of pGx708. 
The possibility that the A domain may contain autoantibody-reac-
tive sites not detected by th e methods used in these studies cannot be 
excluded, nor can the possibility that binding of autoantibodies to 
epitopes in Fn III regions secondarily influence the conformation 
and function of the A domain be excluded. The results suggest that 
if autoantibodies contribute to lamina densa - dermal dysadhesion 
by interfering with C7 function , the Fn III repeats may be impor-
tant to that function. No clear function for Fn III repeats in C7 has 
been identified, but the repeats may contribute to the conformation 
of the NCt domain of C7 or possibly contribute to intermolecular 
or intramolecular interactions that are essential to C7 interactions 
with cell s or matri x proteins. Those functions ofFn III repeats could 
conceivably be disrupted by autoantibodies. These results also 
showed a similar profile of epitope recognition by EBA and bullous 
SLE sera suggesting that phenotypic differences between the dis-
eases may not be due to differences in epitope recognition [1 ,2] . 
This work was SHpported ill part by grallts AR07369, AR30475, alld AR10546 
frOIll tire Nat iollal Illstitlites oj Healtlr. 
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